Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6560-6569

  Terabe, Masaki ^a   Ambrosino, Elena ^a   Takaku, Shun ^a   O'Konek, Jessica J ^a   Venzon, David ^a   Lonning, Scott ^b   McPherson, John M ^b   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E749-57 PEPTIDE VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; MONOCLONAL ANTIBODY 1D11; MONOCLONAL ANTIBODY PC61; PEPTIDE VACCINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENTIATION; MONOTHERAPY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; IMMUNOSUPPRESSION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; VACCINES, SUBUNIT;

EID: 70350738483     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1066     Document Type: Article

References (44)

1. Terabe M, Matsui S, Park J-M, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte- mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-1752 (Pubitemid 37494166)
2. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003;63:1860-1864
3. Cottrez F, Groux H. Regulation of TGF-β response during T cell activation is modulated by IL-10. J Immunol 2001;167:773-778 (Pubitemid 32660831)
4. Thomas DA, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8: 369-380 (Pubitemid 41579832)
5. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancerexpanded myeloid-derived suppressor cells induce anergy of NK cells through membranebound TGF-β1. J Immunol 2009;182:240-249
6. Trotta R, Col JD, Yu J, et al. TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008;181: 3784-3792
7. Li MO, Flavell RA. TGF-β: a master of all T cell trades. Cell 2008;134:392-404.
8. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238
9. Nam JS, Terabe M, Kang MJ, et al. Transforming growth factor {β} subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68: 3915-3923
10. Teicher BA. Transforming growth factor-β and the immune response to malignant disease. Clin Cancer Res 2007;13:6247-6251 (Pubitemid 350075011)
11. Yang L, Huang J, Ren X, et al. Abrogation of TGF β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008;13:23-35. (Pubitemid 350309741)
12. Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-Va14Ja18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202: 1627-1633 (Pubitemid 41815868)
13. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008;101: 277-348.
14. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-5283
15. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-b1 gene results in multifocal inflammatory disease. Nature 1992;359:693-700
16. Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000;12:171-181 (Pubitemid 30398631)
17. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993;90: 770-774 (Pubitemid 23028947)
18. Lucas PJ, McNeil N, Hilgenfeld E, et al. Transforming growth factor-β pathway serves as a primary tumor suppressor in CD8+ T cell tumorigenesis. Cancer Res 2004;64:6524-6529 (Pubitemid 39297909)
19. Diebold RJ, Eis MJ, Yin M, et al. Early-onset multifocal inflammation in the transforming growth factor β 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A 1995;92: 12215-12219 (Pubitemid 26014041)
20. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L, Allen JB. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor β 2aff inity purification. J Immunol 1989; 142:1536-1541 (Pubitemid 19086319)
21. Ruzek MC, Hawes M, Pratt B, et al. Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 2003;25:235-257 (Pubitemid 36597420)
22. Morris JC, Shapiro GI, Tan AR, et al. Phase I/II Study of GC1008: a human anti-transforming growth factor-β (TGFb) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008;26.
23. Chen YH, Chiu NM, Mandal M, Wang N, Wang CR. Impaired NK1+ T cell development and early IL-4 production in CD1- deficient mice. Immunity 1997;6:459-467 (Pubitemid 27208201)
24. Hung CF, Cheng WF, Hsu KF, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001;61: 3698-3703
25. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitopecontaining peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249
26. Sarobe P, Pendleton CD, Akatsuka T, et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 1998;102:1239-1248 (Pubitemid 28436284)
27. Thornton AM. Fractionation of T and B cells using magnetic beads. Curr Protoc Immunol 2003. Chapter 3: Unit 3 5A.
28. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma- reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999;162:2227-2234 (Pubitemid 29288845)
29. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162:989-994 (Pubitemid 29035425)
30. Derby MA, Alexander-Miller MA, Tse R, Berzofsky JA. High avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low avidity CTL. J Immunol 2001;166:1690-1697 (Pubitemid 32114651)
31. Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J Immunol 2003;170: 2523-2530 (Pubitemid 36245642)
32. Nomura T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol 2005;293: 287-302.
33. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV- 16. J Immunol 2001;167:6471-6479 (Pubitemid 33081581)
34. Kim S, Buchlis G, Fridlender ZG, et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res 2008;68:10247-10256
35. Ueda R, Fujita M, Zhu X, et al. Systemic inhibition of transforming growth factor-β in gliomabearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009;15:6551-6559
36. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol 1998; 16:137-161
37. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;7:1118-1122
38. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996;93:4102-4107
39. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998;187:1647-1657 (Pubitemid 28235106)
40. Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA. IL-15/IL-15R á-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A 2004;101:15154-15159 (Pubitemid 39391734)
41. Nam JS, Terabe M, Mamura M, et al. An antitransforming growth factor {β} antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008; 68:3835-3843
42. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest 1993;92: 2569-2576
43. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008;205:2221-2234
44. Carlos TM. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc Biol 2001;70:171-184